Oppenheimer Issues Pessimistic Forecast for enGene (NASDAQ:ENGN) Stock Price

enGene (NASDAQ:ENGN) had its price objective dropped by research analysts at Oppenheimer from $33.00 to $30.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 310.96% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Citizens Jmp boosted their target price on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. UBS Group lifted their price objective on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research report on Wednesday, November 12th. Morgan Stanley boosted their price objective on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. Finally, Guggenheim restated a “buy” rating on shares of enGene in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.86.

enGene Trading Up 6.1%

Shares of ENGN stock opened at $7.30 on Wednesday. enGene has a 12-month low of $2.65 and a 12-month high of $12.25. The company has a market capitalization of $489.03 million, a P/E ratio of -3.24 and a beta of -0.29. The firm has a 50-day moving average price of $9.43 and a 200 day moving average price of $8.10. The company has a quick ratio of 6.30, a current ratio of 11.75 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.11. Research analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC bought a new position in enGene in the 2nd quarter valued at $280,000. Paloma Partners Management Co bought a new stake in shares of enGene during the second quarter worth $38,000. Perceptive Advisors LLC raised its position in shares of enGene by 179.8% during the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after acquiring an additional 3,771,840 shares during the last quarter. Cormorant Asset Management LP lifted its stake in shares of enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after acquiring an additional 1,676,405 shares during the period. Finally, Eversept Partners LP acquired a new position in shares of enGene during the fourth quarter valued at $4,116,000. Institutional investors own 64.16% of the company’s stock.

Key Headlines Impacting enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Seeking Alpha highlights major near‑term clinical catalysts: detalimogene voraplasmid showed a 63% complete response rate at 3 months in NMIBC, favorable tolerability, pivotal cohort enrollment above targets, a planned LEGEND cohort update at a spring 2026 medical conference, and an anticipated BLA submission in H2 2026 — all of which support upside if validated. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy and materially raised earnings estimates across multiple quarters/years (Q2–Q4 2026, FY2026–2030), including a long‑term FY2030 EPS upgrade to $0.70 and a $25 price target — analyst upgrades increase credibility of the program and can attract more buy‑side interest. Article Title
• Neutral Sentiment: Some media coverage continues to repeat the HC Wainwright note and buy rating; this amplifies visibility but is largely derivative of the firm’s research rather than new company disclosures. Article Title
• Negative Sentiment: Oppenheimer trimmed its price target from $33 to $30 while keeping an “outperform” rating — a target cut can temper enthusiasm and cap near‑term upside expectations despite continued analyst support. Article Title

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.